Consenso sobre la biopsia selectiva del ganglio centinela en el cáncer de mama. Revisión 2013 de la Sociedad Española de Senología y Patología Mamaria

Bernet, Laia; Piñero, Antonio; Vidal-Sicart, Sergi; Peg, Vicente; Giménez, Julia; Algara, M.; Dueñas, Basilio; Tresserra, F.; Cano, Rafael; Ferrera, José Manuel Cordero; Navarro, Beatriz; Torró, Josep; Pardo, Ricardo; Ramos, David Martínez; Elola, A.; Vallejos, Virginia; Benito, Marina Álvarez; Povedano, J. L. Raya; Gómez, Carmen Carreira; Monge, Josefa Galobardes; Iglesias, Edelmiro; Fuster, Carlos; Lluch, Ana; Agulló, Ángel Martínez

doi:10.1016/j.senol.2013.11.003

Cited by 18 publications

(2 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nowadays, its contribution to the improvement of BC patient staging and prognosis has been widely reported [31]. In fact, LN assessment with OSNA assay and the evaluation of the TTL as a quantitative score of the metastatic burden of the patients is recommended for the management of BC patients in the SESPM (Spanish Society of Senology and Breast Pathology) and the NICE (National Institute for Health and Care Excellence) guidelines [32][33][34]. This technique provides quick and standardized results at in-house diagnostic laboratories, which prompts the patient's diagnosis and treatment tailoring since central laboratories are not required for a reliable LN assessment.…”

Section: Discussionmentioning

confidence: 99%

OPTimizing Irradiation through Molecular Assessment of Lymph node (OPTIMAL): a randomized open label trial.

Algara

Rodrı́guez

Beato

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Conservative surgery followed by breast and nodal irradiation is the standard loco-regional early breast cancer (BC) treatment for patients with four or more involved lymph nodes (LN). However, the treatment strategy when fewer nodes are involved remains unclear, especially when lymphadenectomy has not been performed. Sensitive nodal status assessment molecular techniques as the OSNA (One-Step Nucleic Acid Amplification) assay can contribute to the definition and standardization of the treatment strategy. Therefore, the OPTIMAL study aims to demonstrate the feasibility of incidental irradiation of axillary nodes in patients with early-stage BC and limited involvement of the SLN. Methods: BC patients who underwent conservative surgery and whose SLN total tumour load assessed with OSNA ranged between 250–15,000 copies/µL will be eligible. Patients will be randomized to receive irradiation on the breast, tumour bed, axillary and supraclavicular lymph node areas (intentional arm) or only on the breast and tumour bed (incidental arm). All areas, including the internal mammary chain, will be contoured. The mean, median, D5% and D95% doses received in all volumes will be calculated. The primary endpoint is the non-inferiority of the incidental irradiation of axillary nodes compared to the intentional irradiation in terms of 5-year disease free survival. Secondary endpoints comprise the comparison of acute and chronic toxicity and loco-regional and distant disease recurrence rates.Discussion: Standardizing the treatment and diagnosis of BC patients with few nodes affected is crucial due to the lack of consensus. Hence, the quantitative score for the metastatic burden of SLN provided by OSNA can contribute by improving the discrimination of which BC patients with limited nodal involvement can benefit from incidental radiation as an adjuvant treatment strategy. Trial registration: ClinicalTrial.gov, NCT02335957; https://clinicaltrials.gov/ct2/show/NCT02335957

show abstract

Section: Discussionmentioning

confidence: 99%

OPTimizing Irradiation through Molecular Assessment of Lymph node (OPTIMAL): a randomized open label trial.

Algara

Rodrı́guez

Beato

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Los colorantes recomendados son el azul de metileno, el azul patente, y el azul de isosulfán. En cuanto al coloide, se marca generalmente con tecnecio 99 (99mTC) (8,18,20); pero también existen otras técnicas mediante el uso de colorante verde de indocianina fluorescente (detectado mediante cámara infrarroja) o 99mTC -tilmanocept de menor tamaño molecular que el 99mTC y por lo tanto absorción más rápida (22). Ambas sustancias penetran en los capilares linfáticos, y fluyen pasivamente a los ganglios linfáticos, depositándose en el primero de la cadena linfática regional a la cual drena el tumor.…”

Section: *Modificado De Rioja M (22)unclassified

El vendaje cohesivo en el tratamiento de la trombosis linfática superficial en mujeres intervenidas de cáncer de mama. Serie de casos

Castro

Yuste-Sánchez

2018

Fisioterapia

View full text Add to dashboard Cite

The use of onestep nucleic acid amplification (OSNA) and tumour related factors in the treatment of axillary breast cancer: A predictive model

Banerjee

Williams

Davidson

et al. 2016

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Consenso sobre la biopsia selectiva del ganglio centinela en el cáncer de mama. Revisión 2013 de la Sociedad Española de Senología y Patología Mamaria

Cited by 18 publications

References 67 publications

OPTimizing Irradiation through Molecular Assessment of Lymph node (OPTIMAL): a randomized open label trial.

OPTimizing Irradiation through Molecular Assessment of Lymph node (OPTIMAL): a randomized open label trial.

El vendaje cohesivo en el tratamiento de la trombosis linfática superficial en mujeres intervenidas de cáncer de mama. Serie de casos

The use of onestep nucleic acid amplification (OSNA) and tumour related factors in the treatment of axillary breast cancer: A predictive model

Contact Info

Product

Resources

About